Drug profile · INN
natalizumab
TYSABRI
natalizumab (TYSABRI) is a integrin alpha-4/beta-7 inhibitor. Associated with Biogen. Route of administration: single-use. Current US regulatory status: approved.
Drug details — natalizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
natalizumab (TYSABRI) is a integrin alpha-4/beta-7 inhibitor. Associated with Biogen. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Integrin alpha-4/beta-7 inhibitor
Primary target: Integrin alpha-4/beta-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is natalizumab?
natalizumab (TYSABRI) is a integrin alpha-4/beta-7 inhibitor. Associated with Biogen. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for natalizumab?
TYSABRI is a marketed brand name for natalizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of natalizumab?
natalizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.